BioGend Therapeutics Co., Ltd. (TPEX:6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
25.95
+0.20 (0.78%)
May 29, 2026, 1:30 PM CST
Market Cap3.23B -6.7%
Revenue (ttm)229.81M +28.0%
Net Income-67.11M
EPS-0.55
Shares Out 124.36M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume188,255
Open26.35
Previous Close25.75
Day's Range25.75 - 26.35
52-Week Range25.55 - 49.15
Beta0.15
Analystsn/a
Price Targetn/a
Earnings DateAug 7, 2026

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was fou... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2025, BioGend Therapeutics's revenue was 222.34 million, an increase of 32.62% compared to the previous year's 167.65 million. Losses were -84.61 million, -27.36% less than in 2024.

Financial Statements